Janssen-Cilag's Stelara has received European approval for the treatment of moderate to severe plaque psoriasis in adults refractory or intolerant to other systemic therapies. Having now been approved in both Canada and the EU, Stelara stands to command significant market share if it is approved in the US and fulfils physicians' expectations.
Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.
Pediatric patients in Canada will become the first to have access to Remicade for treating moderately to severely active ulcerative colitis, following Health Canada's approval of the drug for this indication. The regulator's decision is likely to pave the way for similar indication extensions for children in other markets.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions